Daily Stock List
Ludwig Enterprises, Inc. (LUDG)
SmallCapInvestorDaily, OTCtipReporter and PennyStockScholar reported today on Ludwig Enterprises, Inc. (LUDG) and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Ludwig Enterprises, Inc. is a broadcasting company offering programming that caters to a fast growing, multi-cultural market. The Company is launching the first nationwide World radio network in the United States. The One™ radio is bringing HD quality digital audio to a wide audience of diverse ages and origins, whose interests go unsatisfied by contemporary domestic programming. The One™ radio is reaching out to a $1.5 trillion marketplace. Ludwig Enterprises lists on the OTC Pink Current Information.
The Company offers The One™ radio receiver, a mobile, multi-channel, and multi-purposed digital 2-way communication device. Ludwig offers 50 channels of digital programming, including Filipino, Pakistani, Hebrew, Chinese, Greek, and Russian; and provides English programming, old time radio shows, news, audio books, educational, and religious programming, and techno and classical music. The One™ radio is an advertiser supported revenue model. Ludwig Enterprises is able to offer the receiver at a competitive one-time fee, without a monthly service fee.
The One™ radio content and programming caters to those calling the United States home for the first time, who are fluent in the language of their country of origin. The One™ also has content designed to bridge generations born in the U.S with their national heritage. This provides a key link to those who wish to maintain contact with news and culture from their home countries as well as connecting them with others domestically who share the same experience.
This week, Ludwig Enterprises' Board of Directors announced a Joint Venture (JV) Agreement with Worthington Financial Services, Inc. - owner and operator of www.MakeMeACouple.com. Ludwig Enterprises and Makemeacouple.com target the 38 million foreign-born residents of the United States. The intention of the JV between Ludwig and Makemeacouple.com is to assist this niche group in meeting, dating and become a family unit all the while maintaining their connection with their parents, family and friends in their motherland through daily radio programs provided by Ludwig.
The Makemeacouple.com site is a place for persons of like cultural characteristics to meet as well as a place where a person of one ethnic background can find someone from another culture. Worthington Financial Services is a boutique business incubator focusing on emerging and untapped or underserved markets. Worthington Financial Services currently owns greater than 50 percent of Ludwig Enterprises. Worthington does not participate in the day-to-day management or operations of Ludwig.
Today, Ludwig Enterprises announced that their Board of Directors would continue their support of the EB-5 qualified foreign investor program. The U.S. Congress recently enacted S.3245 extending parts of the EB-5 program for an additional three-year period. Under the program, a foreign investor could invest in a license for one or a pool of Ludwig's U.S. (domestic) market areas. Currently, Ludwig has designated 25 opportunities for EB-5 Investors - Detroit, Chicago, New York, Los Angeles, and more.
Ludwig Enterprises, Inc. (LUDG), closed Thursday’s session at $0.0758, down 24.20%, on 1,161,276 volume with 130 trades. The average volume for the last 60 days is 37,170 and the stock's 52-week low/high is $0.03/$0.15.
Obscene Jeans Corp. (OBJE)
OTC Stock Pick, OTCPicks, PennyTrader Publisher, and Best Microcap Stock reported earlier on Obscene Jeans Corp. (OBJE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Obscene Interactive, a subsidiary of OBJ Enterprises, Inc. (OBJE), is an emerging international developer of social gaming applications. Their plan is to introduce innovative technology platforms that enhance the gaming experience across a variety of digital platforms. OBJE's technology platform enables their titles to be accessible to a wide audience of consumers globally, supporting multiple platforms for universal appeal. OBJE has their corporate headquarters in Sarasota, Florida.
OBJE has partnerships with game and technology developers and interactive gaming is a new direction for Obscene Interactive. The Company is working to capitalize on the rapid adoption of mobile and PC-based gaming applications across many age groups. Currently, OBJE is in talks with expert game developers and existing companies with the experience and knowledge to create premier games. These entities, the Company's future partners, will help develop the next level of gaming applications and deliver them to a global market.
Mr. Paul Watson is OBJE's President and Chief Executive Officer. Experienced in business development, he is a seasoned executive with experience in fund raising for startups, growth capital and pre-IPO (Initial Public Offering) financing in the United States and internationally. Mr. Watson started his career working with technology start-up companies as an advisor to the Houston Technology Center, developing business plans and raising funds for entrepreneurs, scientists and small business owners. He continues to advise a number of boards and executive management teams to expand sales growth, worldwide distribution channels, as well as shareholder value.
Earlier this month, Novalon Games, the gaming developer founded by the Joint Venture of OBJ Enterprises (OBJE) and Source Street, LLC, unveiled new details about their debut game, "Wayfarers," on their website. Constructed using the award-winning 3D MMORPG framework HeroEngine, "Wayfarers" will feature a unique mixture of one-on-one battles and tower-defense strategy games. OBJE and Source Street plan to release a demo version of the game before the end of 2012 and the full version in early 2013.
By way of OBJE's Joint Venture partnership with Source Street, the Company is quickly developing their own free-to-play mobile game in-house with Novalon Games. Novalon is an independent game developer.
Obscene Jeans Corp. (OBJE), closed Thursday’s session at $0.045, even for the day, on 5,200 volume with 4 trades. The average volume for the last 60 days is 30,996 and the stock's 52-week low/high is $0.02/$0.50.
eDiets.com, Inc. (DIET)
StreetInsider and SmarTrend Newsletters reported earlier on eDiets.com, Inc. (DIET), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Fort Lauderdale, Florida, eDiets.com, Inc. is a leading provider of weight loss services, information, and products. Their flagship website is www.ediets.com. eDiets.com has been offering subscriptions to their online weight-loss program in the United States since 1998, when they launched their first diet plan. The Company's shares trade on the OTCBB.
The Company earns revenue in five ways. They sell subscriptions to their online weight-loss program and they sell subscriptions to their home meal delivery weight loss program. They generate licensing revenues for the use of their intellectual property (IP), and development/consulting revenues for the design and implementation of private-label nutrition websites. Additionally, they sell advertising throughout their content assets. These are the Company's diet, fitness, and healthy lifestyle-oriented web sites. Furthermore, they sell diet, nutritional, and fitness products via their online store.
eDiets.com personalizes their online programs according to an individual's weight goals, and food and cooking preferences. Members have access to shopping lists, recipes, and weight management tools. eDiets.com offers more than 20 different digital diet plans. They have developed some of these and some they have licensed from third parties.
The Company's meal delivery service ships chill-fresh, nutritionally balanced meals, snacks, and desserts directly to customers. Customers can choose a 5-day or 7-day plan that includes breakfast, lunch, dinner, and a snack. eDiets.com's online and meal delivery subscribers have access to a wide spectrum of support services. These services include access to registered dietitians, nutritionists, a fitness expert, interactive online information, online communities, articles, message boards, and online meetings.
Earlier this week, eDiets.com announced that Mr. Tom Connerty resigned from his position as President and Chief Executive Officer and as a member of the Company's Board of Directors, effective immediately. The Board of Directors has appointed Chief Operating Officer Jennifer Hartnett as President and Chief Executive Officer.
Mr. Connerty said, "During my tenure as President and Chief Executive Officer, we have made meaningful progress on many of our strategic objectives, including stabilizing the Company's meal delivery business, developing a new creative marketing strategy and introducing new product offerings. Given these accomplishments, the recent sale of the Company's corporate services business and pending acquisition by As Seen on TV, Inc., I believe that the foundation for the next phase of the business is firming up and it is the appropriate time for me to move on to other activities."
Ms. Hartnett joined eDiets.com in February of 2011 as Chief Marketing Officer responsible for the strategy, analysis and planning of all marketing, including customer acquisition, retention and reactivation. In February 2012, she was named Chief Operating Officer.
eDiets.com, Inc. (DIET), closed Thursday’s session at $0.32, even for the day. The average volume for the last 60 days is 7,937 and the stock's 52-week low/high is $0.15/$0.90.
Proteonomix, Inc. (PROT)
Bull in Advantage reported recently on Proteonomix, Inc. (PROT), Stocks That Move, Top Down Analyst, Investors Underground did earlier, and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Proteonomix, Inc. is a biotechnology company focusing on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteonomix' shares trade on the OTC Bulletin Board; the Company is based in Mountainside, New Jersey.
Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to concentrate on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine.
Proteonomix' Proteoderm enterprise has developed the aforementioned line of anti-aging skin care cosmetics based on stem cell derivatives. Proteoderm is the first company to use a matrix of proteins originally derived from non-embryonic stem cells, Matrix NC-138, to harness the anti-aging potential of stem cells in cosmeceutical products. Proteoderm does not use enzymes, collagen or growth factors. Moreover, Proteoderm does not utilize embryonic stem cells as a source for their anti-aging skin care products. The Matrix NC-138 line of skin care products includes a cleanser, exfoliator, day cream, night cream, and under eye serum.
Proteonomix is developing their Post Myocardial Infarction treatment, StromaCel™. This treatment is taken intravenously in the first 14 days following an infarction to help to rebuild the underlying vascular tissue to increase cardiac muscle recovery. The Company is currently seeking funding to make an application for FDA Clinical trials on this treatment.
Earlier this month, Proteonomix announced that their clinical trial of UMK-121 received IRB (Institutional Review Board) approval. The clinical trial is now ready for the recruitment of patients. The University of Medicine & Dentistry of New Jersey (UMDNJ) provided the IRB. The Company states that the university made a valuable contribution to this study of the UMK-121 drug therapy on patients with End Stage Liver Disease.
Proteonomix entered into an Agreement to conduct the clinical trial with the UMDNJ. That Agreement required Proteonomix to pay expenses associated with the clinical study, which the Company has done to date.
Proteonomix, Inc. (PROT), closed Thursday’s session at $0.60, up 15.38%, on 55,512 volume with 31 trades. The average volume for the last 60 days is 70,078 and the stock's 52-week low/high is $0.40/$2.95.
Seven Arts Entertainment, Inc. (SAPX)
MonsterStocksPicks, Stock Stars, Street Insider, The Online Investor, OTCPicks, and Stock Analyzer reported recently on Seven Arts Entertainment, Inc. (SAPX), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Seven Arts Entertainment, Inc. is the successor to Seven Arts Pictures Plc. Seven Arts Pictures was founded in 2002 as an independent motion picture production and distribution company. Their focus was the development, acquisition, financing, production and licensing of theatrical motion pictures for exhibition in domestic (U.S. and Canadian) and foreign theatrical markets, and for subsequent global release in other forms of media. Seven Arts Entertainment has their headquarters in Los Angeles, California. They also have offices in London, UK, and New Orleans, Louisiana.
Seven Arts Entertainment develops, finances, and produces films with budgets of $2-$60 million. They license these films worldwide. Their film library now stands at 33 completed motion pictures. Their library also includes 5 motion pictures for which the Company has a judgment confirming their ownership, which they are now seeking to enforce.
Seven Arts Entertainment's intention is to expand their distribution in the fast developing digital transmission platform for film and music. Recently, the Company entered the record and music business and acquired the rights to the recording agreements and masters of the established urban artists DMX and Bones Thugs-n-Harmony.
The Company released the movie Pool Boys in association with Cinedigm on 100 screens in 50 markets in the U.S. in September 2011. They acquired the film Yellow directed by Nick Cassavetes for distribution this past summer. Seven Arts Entertainment's current projects include Neuromancer and The Winter Queen. These are both larger budget films ($60 million and $17 million respectively). The Company's strategy includes financing, producing and distributing 3 to 5 motion pictures in-house per year.
This week, Seven Arts Entertainment announced their results of operations for the fiscal year ended June 30, 2012. They reported a gross profit of $3,468,263 on total revenue of $8,363,904 for the fiscal year ended June 30, 2012. This is in comparison to a gross loss of $119,608 on revenues of $3,328,388 for the Company's listing predecessor Seven Arts Pictures plc for the fiscal year ended June 30, 2011.
The increase in revenue was due to the previously announced accrual of the expected proceeds from disposition of Louisiana and Federal historic rehabilitation and film infrastructure tax credits. The Company also announced this week the appointment of Mr. David Furth to their Board of Directors effective October 15, 2012. Mr. Furth is a managing director of a hedge fund and a private equity investor.
Seven Arts Entertainment, Inc. (SAPX), closed Thursday’s session at $0.125, off by 3.85%, on 191,925 volume with 34 trades. The average volume for the last 60 days is 153,222 and the stock's 52-week low/high is $0.15/$0.58.
Coalspur Mines Ltd. (CSPZF)
We are highlighting Coalspur Mines Ltd. (CSPZF), here at the QualityStocks Daily Newsletter.
Coalspur Mines Ltd. engages in the acquisition, exploration, and development of thermal coal resource projects primarily in Canada. The Company is a coal exploration and development enterprise with approximately 55,000 hectares of coal exploration leases located within the Hinton region of Alberta. Coalspur Mines lists on the OTC Pink Current Information. The Company has their operations office in Calgary, Alberta. They also have offices in Hinton, Alberta, and West Perth, Australia.
Coalspur Mines' goal is to develop a major new thermal export coal region in Alberta to meet growing energy demands globally, particularly the Asia Pacific market. The Company's flagship coal project is the Vista Coal Project. This project has the potential to be one of the largest export thermal coalmines in North America.
The Vista Coal Project covers approximately 10,000 hectares. It contains more than 20km of continuous gently dipping strike length and a Measured and Indicated Coal Resource base of more than 985 million tonnes of low sulphur, high volatile bituminous, export quality thermal coal. Coalspur Mines' completed Bankable Feasibility Study (BFS) on the Vista Coal Project defined a marketable reserve of over 313 million tonnes (Mt) from a recoverable reserve of 566Mt.
The BFS completed in January of this year. The BFS defined a 30-year mine life producing approximately 11.2 million tonnes per annum (Mtpa) of saleable coal from the processing of approximately 20.4Mtpa of run of mine coal. The BFS defined a two-phased approach to project development. Phase 1 foresees production of 5.0Mtpa at a capital cost of C$864 million. Phase 2 foresees increasing production by a further 6.2Mtpa using free cash flow from Phase 1 to fund development.
Coalspur Mines also holds leases directly south of Vista in the Vista South Coal Project. Vista South covers approximately 23,300 hectares and extends for over 25km. Vista South contains a Measured and Indicated Coal Resource of 471Mt and Inferred Coal Resources of 605Mt. The Company will continue exploration drilling on Vista South to further confirm the geological structure in the area and provide data for future technical studies.
In addition, Coalspur owns approximately 14,400 hectares of coal leases located on the northeast boundary of Vista (Vista Extension). They acquired Vista Extension in April of this year. The Company has completed an initial resource estimate that resulted in a Measured and Indicated Coal Resource of 173Mt and Inferred Coal Resources of 969Mt.
Coalspur Mines Ltd. (CSPZF), closed Thursday’s session at $1.07, up 25.00%, on 20,100 volume with 8 trades. The average volume for the last 60 days is 4,329 and the stock's 52-week low/high is $0.576/$2.06.
Discovery Ventures, Inc. (DVN.V)
Today we are highlighting Discovery Ventures, Inc. (DVN.V), here at the QualityStocks Daily Newsletter.
Discovery Ventures, Inc. is a natural resource development company that lists on the TSX Venture Exchange. The Company's mission is to explore for and develop gold, silver, and copper mineral deposits in the province of British Columbia. Discovery Ventures is currently focusing on three core assets. Incorporated in 1999, the Company has their corporate headquarters in Vancouver, British Columbia.
Discovery Venture's assets include the Redbird/Rabbitt claims, located in southern British Columbia in the Similkameen Mining Division. Their assets also include the Bralorne claims located in southern British Columbia in the Lillooet Mining Division, whose mining camp historic gold production totaled 4.15 million ounces of gold from 52 separate veins. In addition, the Company's assets include the Big Creek property located approximately 47 kilometers northeast of the Taseko Mines Prosperity Porphyry copper deposit.
The Redbird/Rabbit project is a gold and silver mining property. The claims consist of 21 mineral tenures totaling 4,085 hectares (10,094 acres). The Bralorne property consists of 35 mineral tenures totaling 5,090 hectares (12,600 acres). The mineral claims are adjacent to, and surround Bralorne Mines Ltd.'s property, and are accessible by paved roads.
Today, Discovery Ventures announced that they signed a Letter of Intent (LOI) to enter into negotiations and to complete technical due diligence with the intent of acquiring up to 80 percent interest in the mineral claims located in the Slocan Mining District of British Columbia (B.C.) known as the Willa Deposit. The LOI will serve as the basis for negotiating a definitive agreement.
The mineral property consists of 5,328 hectares and is south of the town of Silverton, B.C. Several operators have extensively explored and developed the deposit. These include Noranda, Rio Algom, BP Minerals, Bethlehem Resources Corp., Northair Mines Ltd., and Hudson Bay Mining & Smelting. An extensive database is under review. It covers work that includes 596 drill holes totaling 189,000 feet (57,250 meters) of core drilling and 8,500 feet (2,575 meters) of underground workings, extensive geophysics, as well as sampling consisting of 17,150 analyses for Au, Cu, and Ag.
Discovery Ventures, Inc. (DVN.V), closed Thursday’s session at $0.29, up 1.75%, on 485,238 volume. The stock's 52-week low/high is $0.13/$0.28.
UEX Corp. (UEX.TO)
Super Stock Picker reported earlier on UEX Corp. (UEX.TO), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Vancouver, British Columbia, UEX Corp. is a uranium exploration and development corporation. The Company is actively involved in 18 uranium projects. The 18 projects, totaling 308,320 hectares (761,875 acres), are situated in the eastern, western and northern perimeters of the Athabasca Basin, the world's richest uranium belt. UEX's shares trade on the Toronto Stock Exchange.
Pertaining to the 18 uranium projects, six are 100 percent owned and operated by UEX; one is a joint venture with AREVA that is operated by UEX. Additionally, ten are joint-ventured with AREVA, and one is under option from JCU (Canada) Exploration Company, Ltd., which is operated by AREVA.
UEX is currently advancing several uranium deposits at their two major projects. These include the Kianna, Anne, Colette and 58B deposits at their 49 percent-owned Shea Creek Project, a joint venture with AREVA in the western Athabasca Basin, and the Horseshoe, Raven and West Bear deposits located at their 100 percent-owned Hidden Bay Project in the eastern Athabasca Basin.
This week, UEX announced the discovery of a new high-grade zone of basement-hosted mineralization, based on results from the continued exploration of the Kianna Deposit on the Shea Creek Project. This new zone, Kianna East, is to the east of the existing Kianna Deposit. It is spatially associated with a second conductive trend.
The holes drilled in the Kianna area were part of a larger 2012 exploration program on the Shea Creek Project that included drilling on the Colette and 58B deposits. The results reported include five directional drill holes in the SHE-118 and SHE-135 series drilled east of the main Kianna deposit that have intersected the new zone, and three holes in the SHE-141 and SHE-114 series drilled to test margins of the northern and southwestern parts of Kianna.
Mr. Graham Thody, President and CEO of UEX, said, "This new discovery significantly opens the potential of Kianna and the overall exploration potential of the area. This basement mineralization is located well outside the current resource at Kianna and in association with a second, previously untested, graphitic conductor. This continues to establish Shea Creek as one of the largest mineralizing systems in the Athabasca Basin."
UEX Corp. (UEX.TO), closed Thursday’s session at $0.59, off by 1.67%, on 29,340 volume. The stock's 52-week low/high is $0.48/$1.17.
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $3.79, up 21.47%, on 37,958 volume with 63 trades. The stock’s average daily volume over the past 60 days is 39,158, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. reported a new agreement today with top Chinese pharma company, Hubei Qianjiang Pharmaceutical Co., Ltd., to co-develop novel cancer drugs based on the company's Methionine Enkephalin-related patents. The end result of proposed pre-clinical/clinical trials, which will be stringently supervised by TNIB's CMO and CSO, Dr. Ronald Herberman and Professor Fengping Shan respectively, will be a branded product marketed in China under the names IRT-101 and IRT-102. Hubei Qianjiang has committed some $1.6M to advancing pre-clinical work and confidence is high at both companies that every step was being taken to ensure that the drug will be fast-tracked into commercial markets, capitalizing on the strength of Phase I&II trails in the U.S., which showed the strong antitumor efficacy of Methionine Enkephalin.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital
GreeneStone Healthcare Corp. (GRST)
The QualityStocks Daily Newsletter would like to spotlight GreeneStone Healthcare Corp. (GRST). Today, GreeneStone Healthcare Corp. closed trading at $1.76, up 3.53%, on 148,332 volume with 95 trades. The stock’s average daily volume over the past 60 days is 12,577, and its 52-week low/high is $0.70/$1.83.
GreeneStone Healthcare Corp. announced today that the company has begun procedures to apply and list on the NYSE-Amex, rallied by recent performance which has brought GRST up to within range of the exchange's Standard 3 definitions. This listing will give the company the kind of exposure to capital needed to really punch through with the recently announced ‘build and buy’ expansion strategy designed to leap frog market dynamics, taking full advantage of the green field opportunity in Canada, as well as growing demand in the underserviced U.S. mental healthcare sector. The company will be looking to hit the 300 bed mark in its in-patient addiction treatment business in the next 24 months and the recent Institute for Clinical Evaluation Sciences report adds significant credence to the ramp up strategy being embraced by GreeneStone.
GreeneStone Healthcare Corp. (GRST) is focused on operating medical and healthcare clinics in Ontario, Canada, offering addiction treatment, colonoscopy, endoscopy, minor cosmetic procedures, and executive health assessment programs. The company adds overflow capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly underserviced healthcare needs.
Ontario's public healthcare cost has grown at a compounded 7.1% rate over the past 10 years, now accounting for approximately $77B in government spending compared to $39B in 2000. This cost explosion is similar for the country as a whole, growing at 7.4% over the same period. The need for practical change to the system is immediate as demand continues to rise.
Governments are increasingly looking to private alternatives to address the growing trade-off between costs vs. service in the public healthcare system. Private services are expanding beyond their traditional place as overflow capacity to relieve wait times. GreeneStone Healthcare is particularly well positioned with a first-mover advantage in mental healthcare – a highly underserviced niche.
The company currently offers its various medical services via three medical clinics. Future plans include establishing partnerships for accelerated growth as well as dual-listing on CNSX. With positive revenue growth and cash flow positive status recently achieved, GreeneStone is methodically extending its vertical expertise in the healthcare industry. Disclaimer
GreeneStone Healthcare Corp. Company Blog
GreeneStone Healthcare Corp. News:
GreeneStone Seeks Amex Listing – New Report Confirms Demand
GreeneStone Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
GreeneStone Supports the Cause of Mental Health with Charitable Foundation
Loans4Less.com, Inc. (LFLS)
The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.10, up 25.00%, on 32,320 volume with 4 trades. The stock’s average daily volume over the past 60 days is 12,274, and its 52-week low/high is $0.01/$0.51.
Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.
Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.
The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.
Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulting on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer
Loans4Less.com, Inc. Company Blog
Loans4Less.com, Inc. News:
Loans4Less.com Provides Preliminary Financial Results for the Third Quarter of 2012
Loans4Less.com, Inc. New Audio Interview With Chairman and CEO Steven M. Hershman
Loans4Less.com, Inc. Announces Engagement of QualityStocks Investor Relations Services.
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.2117, up 3.27%, on 618,047 volume with 192 trades. The stock’s average daily volume over the past 60 days is 258,575, and its 52-week low/high is $0.1771/$0.595.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
DUMA - Duma Energy Corp, Zacks Initiating Coverage
Duma Energy Corp. Partners with Hydrocarb to Explore for World Class Reserves in Africa Oil Concession
Duma Energy Receives Approval From Government of Namibia for Exploration License Issued for 5.3 Million-Acre Concession
To say simply that everything is going digital offers no clue as to the enormity of the information revolution. Information, other than that carried in the human mind, is essentially any abstract parallelism to the physical world and, as such, it is unlimited in its potential volume. 50 years ago such a notion would itself have been an abstraction of no real importance because the formal production and storage of information was constrained, an activity performed primarily by a few. The average small business operated with an information base that could fit in a half-dozen file cabinets. Today, with billions of people now to enter, reproduce, and compress information at the push of a button, the sheer volumes of data that individuals and organizations routinely process, and demand access to, is becoming a global issue.
It’s this growing flood of information, coupled with ongoing advances in data communication, that are driving cloud processing as never before. Cloud processing offers the only way that businesses, or individuals, can have access to everything, at any time, from any place. The growth of cloud processing, as impressive as it has been, pales in comparison to its expected growth over just the next several years. The estimates are varied, and some would say almost meaningless, because there are so many areas of application.
GlobalWise Investments is taking advantage of all of this from two different directions. First, the company, through its wholly owned subsidiary Intellinetics, is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for small to mid-sized businesses. That is, they offer advanced software solutions that allow private or public organizations to easily store and access huge numbers of documents of any type. Secondly, although ECM can be operated in a stand-alone configuration, GlobalWise is leading the drive to cloud-based ECM, allowing clients universal access to their information base from anywhere in the world.
With a leg in both ECM and cloud technologies, GlobalWise is in an especially strong position. An example of the cloud’s potential is WorkDay, Inc. (NYSE: WDAY), provider of cloud-based applications for enterprises in the U.S. and internationally. In 2007, the company was at roughly $1/2 million in annual sales. Today they stand at approximately $220 million. Such growth required an extensive investment in R&D, Sales, and Marketing. With a fully developed software platform and channel distribution model, GWIV is incurring only nominal costs, and is currently expected to generate the following:
2011: $1.7 million
2012: $3.3+ million
2013: $5+ million
To learn more about GlobalWise and its software solutions, visit www.GlobalWiseInvestments.com
TNI BioTech and Hubei Qianjiang Pharmaceutical, a leading Chinese pharmaceutical company, this morning told the public that they have signed an agreement to co-develop new cancer drugs based on TNI BioTech’s patents involving Methionine Enkephalin. Once approved, the therapies will be marketed in China under the brand names IRT-101 and IRT-102.
Under the supervision of Dr. Ronald Herberman, Chief Medical Officer, and Professor Fengping Shan, Chief Science Officer, TNI BioTech will be responsible for overseeing pre-clinical and clinical trials in China, complying with both FDA and SFDA standards. The companies believe this venture partnership will fast track the drugs for introduction to the Chinese pharmaceutical markets.
Hubei Qianjiang Pharmaceutical has committed a minimum of 10 million yuan (approximately $1.6 million dollars) for pre-clinical work. The pre-clinical trials designed to assess safety, tolerability, and antitumor activity of Methionine Enkephalin are required in China as Methionine Enkephalin is a new drug.
After completion of the pre-clinical studies, TNI BioTech will apply for clinical trials with SFDA. Hubei Qianjiang Pharmaceutical will provide the funding for clinical trials in China to have Methionine Enkephalin approved as a new drug for the treatment of cancer. Methionine Enkephalin’s potential in fighting cancer was identified in completed Phase I and early phase II trials in the United States. During Phase I and Phase II trials, Methionine Enkephalin exhibited encouraging antitumor efficacy and a favorable toxicity profile.
“This alliance with TNI BioTech validates Hubei Qianjiang Pharmaceutical Co., Ltd.’s business model of co-developing novel compounds as therapies for Chinese markets in conjunction with a U.S. biotech company,” stated Mr. Ye Jige, President of Hubei Qianjiang Pharmaceutical Co., Ltd. “The initiation of the pre-clinical trials for IRT-101 and IRT-102 in China is a significant achievement for the development of Hubei Qianjiang Pharmaceutical Co., Ltd. and it represents both an important development milestone for this promising cancer drug and illustrates the benefits of Chinese and Western biopharmaceutical companies working together to efficiently carry out drug development. This important step will expedite the clinical development process of IRT-101 and IRT-102 in China.”
Noreen Griffin, CEO of TNI BioTech, added, “This agreement illustrates TNI BioTech’s ability to draw upon its patents to build alliances that help biopharmaceutical companies navigate the approval process of new therapies and further illustrates our strategy to maximize the potential of biopharmaceutical development and innovation for the benefit of patients and our shareholders.”
For more information, visit www.TNIBiotech.com
Today before the opening bell, GreeneStone Healthcare announced that it will begin the application process to list on the NYSE-Amex exchange. Following the company’s recent performance, GreeneStone has met, or nearly met, the listing requirements for the NYSE-Amex under its Standard 3 definitions.
The NYSE-Amex listing is believed to best serve GreeneStone’s needs as management pursues capital to support the recently announced ‘build and buy’ expansion strategy. This strategy is designed to take advantage of the numerous opportunities within the underserviced mental healthcare sector in Canada and the US. The expansion strategy’s first projected milestone is to reach the 300 bed level in its in-patient addiction treatment business in the next twenty-four months.
The huge demand for mental healthcare services identified by the company early on has been confirmed by a recently released report. The report was released last week by the Institute for Clinical Evaluation Sciences (ICES) and Public Health Ontario. The report demonstrates that “the burden of mental illness and addictions in Ontario is more than 1.5 times that of all cancers and more than seven times that of all infectious diseases.” The report goes on to say “five conditions have the highest impact on the life and health of Ontarians: depression, bipolar disorder, alcohol use disorders, social phobia and schizophrenia.”
Research has shown that mental disorders and addictions are very prevalent. In fact, one in five Canadians are estimated to experience a mental disorder at least once a year. Mental conditions and addictions cost Canada an estimated forty to fifty billion dollars annually. Last week’s study confirms that the burden of mental disorders and addictions is very high and outstrips the burden of many physical illnesses.
“This report does not surprise me, the numbers are staggering,” commented Shawn Leon CEO of GreeneStone. “The awareness of mental health is growing and we are set to carve out a niche in this sector.”
ICES is an independent, non-profit organization that produces knowledge to enhance the effectiveness of healthcare for Ontarians. To access the 6-page summary and full report, visit the ICES Web site
For more information on GreeneStone Healthcare, visit www.GreeneStoneInvestor.com
Amarantus BioSciences announced it has received a Translational Research Grant award from the University of Massachusetts’ Pioneer Valley Life Sciences Institute’s Center of Excellence in Apoptosis Research (CEAR). The institute is a joint research venture between Baystate Medical Center and the University of Massachusetts Amherst.
Amarantus is a biotechnology company engaged in the development of new treatments for brain-related disorders, including Parkinson’s disease and traumatic brain injuries (TBI), and the company is centered on its unique proprietary anti-apoptotic therapeutic protein known as MANF. Investigators for the joint study with UMass Amherst will utilize publicly available genomics databases to identify new potential therapeutic targets for MANF-based therapeutics; they will then validate those hypotheses in cell-based laboratory research. The program could potentially lead to the identification and patenting of therapeutic indications for MANF that are beyond what has already been reported.
Literature relating to MANF has increased greatly in recent years, and there seems to be a solid rationale for investigating its potential uses in areas other than Parkinson’s disease. The study will complement work being done by other labs around the world that are focusing on MANF. The University of Massachusetts’ relationship with Amarantus will be critical in ensuring that the basic science behind MANF can be translated into clinical research in various other therapeutic indications.
The UMass grant will enable Amarantus to explore the full spectrum of the MANF opportunity. As Amarantus’ development program for Parkinson’s continues toward identifying MANF’s best delivery targets, the identification of additional disease targets for MANF therapy could greatly increase the value of the company’s intellectual property portfolio and, by extension, make Amarantus more attractive to potential partners.
Amarantus BioSciences is a development-stage biotechnology company. Founded in 2008, the company is focused on developing certain biologics surrounding the intellectual property and proprietary technologies it owns for treating and diagnosing Parkinson’s disease, traumatic brain injury, and other diseases. Amarantus owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF). The company is currently developing MANF-based products to be used as treatments for brain disorders and is also a founding member of the Coalition for Concussion Treatment. This movement, initiated in collaboration with Brewer Sports International, seeks to raise awareness of new treatments that are in development for concussions and nervous-system disorders.
For more information, visit www.Amarantus.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Announces New Channel Partnership With Level Seven
- GreeneStone Healthcare Corp. (GRST) Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
- International Stem Cell Corp. (ISCO) Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
- Loans4Less.com, Inc. (LFLS) New Audio Interview With Mr. Steven M. Hershman, Chairman and CEO via SmallCapVoice
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- Teletouch Communications, Inc. (TLLE) Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl
- TNI BioTech Inc. (TNIB) Dr. Henry "Skip" Lenz, Pharm.D, Joins the Company as Quality Control Officer
- VistaGen Therapeutics, Inc. (VSTA) Announces Strategic Financing With Platinum Long Term Growth Fund